Erste Asset Management Gmb H Revance Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Nov 26, 2024	SELL	$11.52 - $20.4 $766,080 - $1.36 Million	-66,500 Closed	0 $0
Q4 2018 Nov 26, 2024	BUY	$18.06 - $24.96 $1.2 Million - $1.66 Million	66,500 New	66,500 $1.3 Billion

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.